Effectiveness of a systematic vaccination program in patients with autoimmune inflammatory disease treated with anti-TNF alpha drugs

References

• Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum. 2010;39:327–346. doi:10.1016/j.semarthrit.2008.10.002.
   PubMed Web of Science ®Google Scholar
• Billiet T, Rutgeerts P, Ferrante M, et al. Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opin Biol Ther. 2014;14:75–101. doi:10.1517/14712598.2014.858695.
   PubMed Web of Science ®Google Scholar
• Lories RJ, de Vlam K. Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity. Expert Opin Biol Ther. 2014;14:1825–1836. doi:10.1517/14712598.2014.967211.
   PubMed Web of Science ®Google Scholar
• Keystone EC. Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data. J Rheumatol. 2011;38:1552–1562. doi:10.3899/jrheum.100995.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Contatore M, et al. Infection risk associated with anti-TNF-α agents: a review. Expert Opin Drug Saf. 2015;14:571–582. doi:10.1517/14740338.2015.1009036.
   PubMed Web of Science ®Google Scholar
• Hutfless SM, Weng X, Liu L, et al. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. Gastroenterology. 2007;133:1779–1786. doi:10.1053/j.gastro.2007.09.022.
   PubMed Web of Science ®Google Scholar
• Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford). 2013;52:53–61. doi:10.1093/rheumatology/kes305.
   PubMed Web of Science ®Google Scholar
• Zisman D, Haddad A, Hashoul S, et al. Hospitalizations of patients treated with anti-tumor necrosis factor-α agents – a retrospective cohort analysis. J Rheumatol. 2013;40:16–22. doi:10.3899/jrheum.111516.
   PubMed Web of Science ®Google Scholar
• Lawrance IC, Radford-Smith GL, Bampton PA, et al. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience. J Gastroenterol Hepatol. 2010;25:1732–1738. doi:10.1111/j.1440-1746.2010.06407.x.
   PubMed Web of Science ®Google Scholar
• Tong Q, Cai Q, de Mooij T, et al. Adverse events of anti-tumor necrosis factor α therapy in ankylosing spondylitis. PLoS One. 2015;10:e0119897. doi:10.1371/journal.pone.0119897.
   PubMed Web of Science ®Google Scholar
• Lefebvre JS, Haynes L. Vaccine strategies to enhance immune responses in the aged. Curr Opin Immunol. 2013;25:523–528. doi:10.1016/j.coi.2013.05.014.
   PubMed Web of Science ®Google Scholar
• Van Assen S, Elkayam O, Agmon-Levin N, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70:414–422. doi:10.1136/ard.2010.139832.
   PubMed Web of Science ®Google Scholar
• Lanternier F, Henegar C, Mouthon L, et al. Low influenza-vaccination rate among adults receiving immunosuppressive therapy for systemic inflammatory disease. Ann Rheum Dis. 2008;67:1047. doi:10.1136/ard.2007.081703.
   PubMed Web of Science ®Google Scholar
• Desai SP, Turchin A, Szent-Gyorgyi LE, et al. Routinely measuring andreporting pneumococcal vaccination among immunosuppressed rheumato-logy outpatients: the first step in improving quality. Rheumatology. 2011;50:366–372. doi:10.1093/rheumatology/keq297.
   PubMed Web of Science ®Google Scholar
• Löbermann M, Boršo D, Hilgendorf I, et al. Immunization in the adult immunocompromised host. Autoimmun Rev. 2012;11:212–218. doi:10.1016/j.autrev.2011.05.015.
   PubMed Web of Science ®Google Scholar
• Hmamouchi I, Winthrop K, Launay O, et al. Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort. Vaccine. 2015;33:1446–1452. doi:10.1016/j.vaccine.2015.01.065.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
   PubMedGoogle Scholar
• Fernandez-Martinez S, Castellano A, Alegre JJ, et al. Vacunación de pacientes adultos con enfermedades reumáticas inflamatorias de origen autoinmune (EIA) Documento de Consenso de la Sociedad Valenciana de Reumatología (SVR) y de la Sociedad Valenciana de Medicina Preventiva y Salud Pública (SVMPSP). Rev Sociedad Val Reuma. 2014;3:3–10.
   Google Scholar
• Bijl M, Kallenberg CG, van Assen S. Vaccination of the immune-compromised patients with focus on patients with autoimmune-inflammatory diseases. Neth J Med. 2011;69:5–13.
   PubMed Web of Science ®Google Scholar
• Baillet A, Gossec L, Carmona L, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. Ann Rheum Dis. 2016;75:965–973.
   PubMed Web of Science ®Google Scholar
• Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology. 2007;46:1157–1160. doi:10.1093/rheumatology/kem045.
   PubMed Web of Science ®Google Scholar
• Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46:2287–2293. doi:10.1002/(ISSN)1529-0131.
   PubMed Web of Science ®Google Scholar
• Culver EL, Travis SP. How to manage the infectious risk under anti‑TNF in inflammatory bowel disease. Curr Drug Targets. 2010;11:198–218. doi:10.2174/138945010790310009.
   PubMed Web of Science ®Google Scholar
• Papadopoulou D, Sipsas NV. Comparison of national clinical practiceguidelines and recommendations on vaccination of adult patients withautoimmune rheumatic diseases. Rheumatol Int. 2014;34:151–163. doi:10.1007/s00296-013-2907-9.
   PubMed Web of Science ®Google Scholar
• Annunziata K, Rak A, Del Buono H, et al. Vaccination rates among the general adult population and high-risk groups in the United States. PLoS One. 2012;7:e50553. doi:10.1371/journal.pone.0050553.
   PubMed Web of Science ®Google Scholar
• Desalermos AP, Farraye FA, Wasan SK. Vaccinating the inflammatory bowel disease patient. Expert Rev Gastroenterol Hepatol. 2015;9:91–102. doi:10.1586/17474124.2014.934672.
   PubMed Web of Science ®Google Scholar
• Kaddar M, Schmitt S, Makinen M, et al. Global support for new vaccine implementation in middle-income countries. Vaccine. 2013;31:B81–B96. doi:10.1016/j.vaccine.2012.11.085.
   PubMed Web of Science ®Google Scholar
• Westra J, Rondaan C, van Assen S, et al. Vaccination of patients with autoimmune inflammatory rheumatic diseases. Nat Rev Rheumatol. 2015;11:135–145. doi:10.1038/nrrheum.2014.206.
   PubMed Web of Science ®Google Scholar
• Cohen V, Jellinek-Cohen SP, Likourezos A, et al. Feasibility of a pharmacy-based influenza immunization program in an academic emergency department. Ann Pharmacother. 2013;47:1440–1447. doi:10.1177/1060028013502456.
   PubMed Web of Science ®Google Scholar
• Bühler S, Eperon G, Ribi C, et al. Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. Swiss Med Wkly. 2015;145:w14159.
   PubMed Web of Science ®Google Scholar